Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
213 hedge funds and large institutions have $2.22B invested in Sage Therapeutics in 2023 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 75 increasing their positions, 54 reducing their positions, and 24 closing their positions.
100% more call options, than puts
Call options by funds: $16.2M | Put options by funds: $8.11M
39% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 54
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
16% more capital invested
Capital invested by funds: $1.92B → $2.22B (+$303M)
3.93% more ownership
Funds ownership: 84.6% → 88.53% (+3.9%)
3% more funds holding
Funds holding: 206 → 213 (+7)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.9M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$20.6M |
| 3 |
Millennium Management
New York
|
+$12.1M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$26.7M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$9.03M |
| 3 |
Janus Henderson Group
London,
|
-$8.62M |
| 4 |
D.E. Shaw & Co
New York
|
-$6.07M |
| 5 |
Morgan Stanley
New York
|
-$5.63M |
SAGE Hedge Fund Activity: Q1 2023 in Review
213 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2023, worth a combined $2.22B — up 16% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new SAGE positions and 24 closed out — a net gain of 9 holders — while 75 added to existing stakes and 54 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $22.9M. The largest seller was Camber Capital Management, exiting entirely with an estimated $26.7M sold.
- 213 institutional investors held Sage Therapeutics (SAGE) as of Q1 2023, up from 206 in Q4 2022.
- Funds reported $2.22B of Sage Therapeutics stock for Q1 2023, up 16% quarter-over-quarter.
- 33 funds opened new Sage Therapeutics positions in Q1 2023 and 24 closed out, a net change of +9 holders.
- The largest Sage Therapeutics buyer in Q1 2023 was Fidelity Investments, an estimated $22.9M added.
- The largest Sage Therapeutics seller in Q1 2023 was Camber Capital Management, an estimated $26.7M sold.
Based on aggregated 13F filings for Q1 2023.